Evidence map›Paper›PMID 29523233›Full record

ArticleMethods in enzymology2018

Targeting Allostery with Avatars to Design Inhibitors Assessed by Cell Activity: Dissecting MRE11 Endo- and Exonuclease Activities.

Davide Moiani, Daryl A Ronato, Chris A Brosey, Andrew S Arvai, Aleem Syed, Jean-Yves Masson, Elena Petricci, John A Tainer

Open access · greenAbstract read
In one paragraph

Article in Methods in enzymology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Davide MoianiThe University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.
Daryl A RonatoGenome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada; Laval University Cancer Research Center, Québec City, QC, Canada.
Chris A BroseyThe University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.
Andrew S ArvaiThe Scripps Research Institute, La Jolla, CA, United States.
Aleem SyedThe University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States.
Jean-Yves MassonGenome Stability Laboratory, CHU de Québec Research Center, Québec City, QC, Canada; Laval University Cancer Research Center, Québec City, QC, Canada.
Elena PetricciUniversity of Siena, Siena, Italy. Electronic address: petricci@unisi.it.
John A TainerThe University of Texas, M.D. Anderson Cancer Center, Houston, TX, United States; Lawrence Berkeley National Laboratory, Berkeley, CA, United States. Electronic address: jatainer@gmail.com.
The University of Texas MD Anderson Cancer Center · USUniversité Laval · CALawrence Berkeley National Laboratory · USScripps Research Institute · USUniversity of Siena · IT

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI WALTER J. CHAZIN · 2001 to 2026
$89.6M
Mre11/Rad50 Structural Biology for DNA Damage ResponsesR01CA117638 · NCI · SCRIPPS RESEARCH INSTITUTE, THE · PI RUSSELL, PAUL, TAINER, JOHN A. · 2005 to 2019
$5.6M
CIHR PJ/375408NCI NIH HHS P01 CA092584NCI NIH HHS R01 CA117638
6 · The paper itself

Abstract

For inhibitor design, as in most research, the best system is question dependent. We suggest structurally defined allostery to design specific inhibitors that target regions beyond active sites. We choose systems allowing efficient quality structures with conformational changes as optimal for structure-based design to optimize inhibitors. We maintain that evolutionarily related targets logically provide molecular avatars, where this Sanskrit term for descent includes ideas of functional relationships and of being a physical embodiment of the target's essential features without requiring high sequence identity. Appropriate biochemical and cell assays provide quantitative measurements, and for biomedical impacts, any inhibitor's activity should be validated in human cells. Specificity is effectively shown empirically by testing if mutations blocking target activity remove cellular inhibitor impact. We propose this approach to be superior to experiments testing for lack of cross-reactivity among possible related enzymes, which is a challenging negative experiment. As an exemplary avatar system for protein and DNA allosteric conformational controls, we focus here on developing separation-of-function inhibitors for meiotic recombination 11 nuclease activities. This was achieved not by targeting the active site but rather by geometrically impacting loop motifs analogously to ribosome antibiotics. These loops are neighboring the dimer interface and active site act in sculpting dsDNA and ssDNA into catalytically competent complexes. One of our design constraints is to preserve DNA substrate binding to geometrically block competing enzymes and pathways from the damaged site. We validate our allosteric approach to controlling outcomes in human cells by reversing the radiation sensitivity and genomic instability in BRCA mutant cells.

Indexed as

Drug DesignAllosteric RegulationAmino Acid SequenceEndonucleasesEvolution, MolecularExonucleasesHumansMRE11 Homologue ProteinProtein ConformationSensitivity and SpecificitySequence AlignmentSequence Analysis, ProteinEndonucleasesExonucleasesMRE11 Homologue ProteinMRE11 protein, humanChemical inhibitorsDNA repair pathwaysDouble-strand breaksEndonucleaseExonucleaseMRE11

Identifiers

PMID29523233
PMCPMC6070142
OpenAlexW2789485290

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.